Researchers from the University of Arizona presented the discovery of first-in-class dual-specificity tyrosine phosphorylation-regulated kinase 1A/B (DYRK1A/B) proteolysis targeting chimeras (PROTACs) as potential Alzheimer’s disease (AD) therapeutic candidates.
The editing in human cells and in mice of the survival motor neuron 1 gene (SMN1) restored the levels of SMN protein that the mutation of the SMN2 gene produces in spinal muscular atrophy. Scientists from the Broad Institute in Boston and The Ohio State University reversed the mutation using the base editing technique.
Beckley Psytech Ltd. is advancing lead BPL-003 psychedelic therapy on two fronts, opening phase IIa trials in alcohol use disorder and in treatment-resistant depression.
The editing in human cells and in mice of the survival motor neuron 1 gene (SMN1) restored the levels of SMN protein that the mutation of the SMN2 gene produces in spinal muscular atrophy (SMA). Scientists from the Broad Institute in Boston and The Ohio State University reversed the mutation using the base editing technique. “This base editing approach to treating SMA should be applicable to all SMA patients, regardless of the specific mutation that caused their SMN1 loss,” the lead author David Liu, a professor and director of the Merkin Institute of Transformative Technologies in Healthcare at the Broad Institute of Harvard and MIT, told BioWorld.
Gliotransmitter release by astrocytes depends on calcium dynamics and is an essential regulator of brain functions. Alterations of calcium homeostasis have been observed in neurons and astrocytes from mouse models of Alzheimer’s disease (AD). A new longitudinal study in the PS2APP mouse model of AD suggests a possible link between calcium dynamics in astrocytes and memory loss.
Calyx (Perceptive Informatics LLC) has entered into a strategic partnership with Ceretype Neuromedicine Inc., whose novel functional magnetic resonance imaging (fMRI) platform incorporates optimal image acquisition and advanced analytics to de-risk and accelerate the development of psychiatric and neurological therapies
Biorchestra Co. Ltd. reached an exclusive research, option and licensing contract with a U.S.-based company to use its targeting technology platform to develop nucleic acid therapies to treat neurological disorders in a deal valued up to $861 million.
RSS
